Clinical germline genetic testing for melanoma

Area of Science:

• Medical Genetics
• Oncology
• Dermatology

Background:

• Clinical genetic testing for CDKN2A (cyclin-dependent kinase inhibitor 2A) mutations, a gene linked to melanoma susceptibility, is now accessible.
• The International Melanoma Genetics Consortium recommends that CDKN2A genetic testing be conducted exclusively within research protocols.

Purpose of the Study:

• To evaluate if clinical CDKN2A genetic testing aligns with the American Society of Clinical Oncology (ASCO) guidelines for cancer-susceptibility genetic testing.
• To explore the potential benefits and limitations of clinical CDKN2A testing for melanoma prevention and detection.

Main Methods:

• Review of existing literature and guidelines regarding cancer-susceptibility genetic testing.
• Analysis of the implications of CDKN2A testing based on experiences with other cancer-susceptibility genes.
• Assessment of clinical applicability versus research protocol requirements for CDKN2A testing.

Main Results:

• CDKN2A genetic testing holds significant potential for early melanoma detection and prevention.
• While research protocols are favored, clinical testing outside these protocols is viable under specific conditions.

Conclusions:

• Clinical CDKN2A testing can be beneficial if patient selection, education, counseling, test interpretation, and medical management modifications are carefully managed.
• Adherence to ASCO recommendations and careful consideration of patient needs are crucial for advantageous implementation of CDKN2A genetic testing.